Good news! Asartan potassium tablets have been approved
May 26, 2026
Source: drugdu
25
Recently, Hefei Lifang Pharmaceutical Co., Ltd. received the Drug Registration Certificate for Mesartan Potassium Tablets ( 40mg , 80mg ) issued by the National Medical Products Administration .
Mesartan potassium is a prodrug of the angiotensin II receptor blocker class. After oral absorption, it is rapidly converted into the active ingredient, azilsartan. The product for which marketing authorization is being applied is azilsartan potassium tablet, indicated for the treatment of essential hypertension in adults. The original manufacturer is Takeda Pharmaceutical Company Ltd. of Japan.
The company's esculent potassium API was approved for marketing in April 2026. The acquisition of the Drug Registration Certificate for esculent potassium tablets will further enrich the company's product pipeline, enhance the company's integrated industrial chain advantages in raw materials and formulations, and improve the company's market competitiveness.
https://mp.weixin.qq.com/s/GxAXMABZsxOGm0mvDJhsxg
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Hisun Pharmaceutical’s prostate cancer treatment drug has been approved for market launch May 26, 2026
- Huadong Medicine’s first precision-targeting EGFR exon 21 (L858R) innovative drug, mefanilinib maleate (Mindray®), was prescribed for the first time nationwide May 26, 2026
- Progen Pharmaceuticals’ metoprolol succinate extended-release tablets have received FDA approval in the United States for a new 25mg specification. May 26, 2026
- Japanese pharmaceutical giant ordered to pay 17 billion yen in damages. May 26, 2026
- Big news! Johnson & Johnson’s new autoimmune drug nicalimab approved in China May 26, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
